Compare Dolby Laboratories, Inc. (DLB) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dolby Laboratories, Inc. vs Johnson & Johnson — how do they compare? Dolby Laboratories, Inc. trades at $58.74 (market cap $5.47B), while Johnson & Johnson trades at $261.44 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 113× Dolby Laboratories, Inc.'s market cap, and Dolby Laboratories, Inc. pays the higher dividend (2.46%). Which is the better fit depends on your goals — on Pluang, investors hold Dolby Laboratories, Inc. for 98 Days and Johnson & Johnson for 129 Days on average.
| DLB | JNJ | |
|---|---|---|
Market Cap | $5.47B | $618.09B |
Volume | 1,058,284 | 6,050,983 |
Sector | Technology | Health |
52-Week High | $69.58 | $278.43 |
52-Week Low | $48.51 | $186.00 |
Typical Hold Time | 98 Days | 129 Days |
Enterprise Value | $4.85B | $646.37B |
Dividend Yield | 2.46% | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dolby Laboratories (DLB) trades at $58.45, showing modest daily gains of 0.17%. The stock faces bearish technical signals with resistance at $59 and support at $58. Fundamentally, DLB maintains strong profitability with 87.61% gross margins and has beaten earnings estimates in three consecutive quarters. Recent developments include expanded partnerships with Meta and leadership transition to new CEO Marc Whitten.
DLB presents a mixed outlook with analyst consensus pointing to significant upside (target $90.33) despite near-term execution risks. The company's strong cash position and expanding digital content partnerships provide growth catalysts, though licensing volatility and competitive pressures remain key challenges for investors.
Johnson & Johnson (JNJ) trades at $256.48, down 0.76% on the day, with the stock showing mixed technical signals amid a bearish overall trend. The company maintains strong fundamentals with $94.19B in 2025 revenue, 21.48% net income margin, and consistent earnings beats in recent quarters. Recent analyst coverage shows 52.5% buy ratings with a $286.53 consensus price target, while technical indicators point to key support at $248 and resistance at $258.
JNJ presents a compelling long-term investment case with robust profitability, diversified healthcare portfolio, and dividend stability, though near-term headwinds include patent expirations and competitive pressures. The stock's current valuation at 29.75 P/E appears reasonable given strong cash flow generation and pipeline innovation, with upside potential to analyst targets if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dolby Laboratories, Inc.
Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company generates three fourths of its revenue from licensing its technology to consumer electronics manufacturers around the world. The rest of revenue comes from equipment sales to professional producers and audio engineering services.
Read more on DLB →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
